Martin and Harris Laboratories Limited
+30752.99 % 1 MAbout Martin and Harris Laboratories Limited
A Comprehensive Overview of Price & Journey
Understanding Martin and Harris Laboratories Limited Inception and Growth
Overview
Martin and Harris Laboratories Ltd, one of India’s leading pharmaceutical companies, has grown leaps and bounds to emerge as a well-reputed organisation for research and manufacturing of finished dosage forms, which was established in 1993.
The company has its units located at Roorkee and UNA Himachal Pradesh. It is constantly taking steps to improve and expand its manufacturing units to meet international standards.
The Company has been awarded “Best Innovative in Process & Formulation Development” by the Director-General of Health Services, Ministry of Health & Family Welfare, Government of India. Has also received “Pharma Excellence Awards 2018” from the apex industry chamber ASSOCHAM.
It also offers a wide range of diversified products and state-of-the-art facilities that include flexible, cost-effective drug development and manufacturing solutions with value-added services.
Business Verticals
-
Pharma business = 52%
-
Derivative and Investment business = 48%
Manufacturing Plants
-
Roorkee Plant
Commenced production in August 2008, the facility at Roorkee (Uttarakhand) includes high-technology pharmaceutical manufacturing equipment & machinery that functions with stringent quality control techniques in accordance with International Guidelines. The factory has a huge capacity for tablets, capsules, dry syrup, liquid orals, ointments & drug powder, as well as new FDF technologies (e.g. dispersible and modified release tablets). There is also a separate section for hormonal products in this unit.
-
Gagret Plant
Commenced production in 2010 with similar attributes as the Roorkee plant, Martin and Harris’ second manufacturing unit at Gagret (Himachal Pradesh) serves as a major site for business continuity and capacity expansion.
Strategic Alliance with Walter Bushnell
Walter Bushnell: Walter Bushnell is one of India’s most renowned pharmaceutical companies with a 100+ years legacy of quality & trust which continues to inspire and was established in 1915.
Board of Directors
-
Mr. S. L. Laad
-
Mr. H. S. Thakur
-
Mr. Nasim Uddin
-
Mr. Vlvek Manohar Padgaonkar
-
Mr. A. Csen
Listing Status
DHRP has not been filed.
IPO details
The Company did not provide any information regarding the IPO plans of the company.
Dividend details
The company paid a dividend of Rs. 5.201- per Equity Share.
Martin and Harris Laboratories Ltd Share Price & Market Information
Investors often look for updates on the Martin and Harris Laboratories Ltd share price as the company continues to grow in the pharmaceutical sector. If you need to monitor the Martin and Harris share price, you can get real-time information from financial websites. With the company proceeding with its expansion agenda, it will be exciting to monitor the performance of the Martin and Harris Laboratories Ltd share price in the days to come.
Martin and Harris Private Limited was the company's past name, and it is sought by individuals conducting research on the history and establishment of the company in the pharma sector.
Subsidiaries
- Delite Infrastructure Private Limited
Registered Office
The Registered office of the company is in Gurgaon, Haryana, India.
SHOW MORE...
Overview
Martin and Harris Laboratories Ltd, one of India’s leading pharmaceutical companies, has grown leaps and bounds to emerge as a well-reputed organisation for research and manufacturing of finished dosage forms, which was established in 1993.
The company has its units located at Roorkee and UNA Himachal Pradesh. It is constantly taking steps to improve and expand its manufacturing units to meet international standards.
The Company has been awarded “Best Innovative in Process & Formulation Development” by the Director-General of Health Services, Ministry of Health & Family Welfare, Government of India. Has also received “Pharma Excellence Awards 2018” from the apex industry chamber ASSOCHAM.
It also offers a wide range of diversified products and state-of-the-art facilities that include flexible, cost-effective drug development and manufacturing solutions with value-added services.
Business Verticals
-
Pharma business = 52%
-
Derivative and Investment business = 48%
Manufacturing Plants
-
Roorkee Plant
Commenced production in August 2008, the facility at Roorkee (Uttarakhand) includes high-technology pharmaceutical manufacturing equipment & machinery that functions with stringent quality control techniques in accordance with International Guidelines. The factory has a huge capacity for tablets, capsules, dry syrup, liquid orals, ointments & drug powder, as well as new FDF technologies (e.g. dispersible and modified release tablets). There is also a separate section for hormonal products in this unit.
-
Gagret Plant
Commenced production in 2010 with similar attributes as the Roorkee plant, Martin and Harris’ second manufacturing unit at Gagret (Himachal Pradesh) serves as a major site for business continuity and capacity expansion.
Strategic Alliance with Walter Bushnell
Walter Bushnell: Walter Bushnell is one of India’s most renowned pharmaceutical companies with a 100+ years legacy of quality & trust which continues to inspire and was established in 1915.
Board of Directors
-
Mr. S. L. Laad
-
Mr. H. S. Thakur
-
Mr. Nasim Uddin
-
Mr. Vlvek Manohar Padgaonkar
-
Mr. A. Csen
Listing Status
DHRP has not been filed.
IPO details
The Company did not provide any information regarding the IPO plans of the company.
Dividend details
The company paid a dividend of Rs. 5.201- per Equity Share.
Martin and Harris Laboratories Ltd Share Price & Market Information
Investors often look for updates on the Martin and Harris Laboratories Ltd share price as the company continues to grow in the pharmaceutical sector. If you need to monitor the Martin and Harris share price, you can get real-time information from financial websites. With the company proceeding with its expansion agenda, it will be exciting to monitor the performance of the Martin and Harris Laboratories Ltd share price in the days to come.
Martin and Harris Private Limited was the company's past name, and it is sought by individuals conducting research on the history and establishment of the company in the pharma sector.
Subsidiaries
- Delite Infrastructure Private Limited
Registered Office
The Registered office of the company is in Gurgaon, Haryana, India.
About Martin and Harris Laboratories Limited
IPO Details, Price movement
Performance Highlights for FY 2023-24
-
Revenue from operation decreased by 29% from INR 205 crore in FY23 to INR 146 crore in FY24.
-
Total Revenue decreased by 21 % from INR 229.2 crore in FY23 to INR 180.4 crore in FY24.
-
Profit Before Tax decreased by 40% from INR 92.1 crore in FY23 to INR 55.2 crore in FY24.
-
The Company’s Profit After Tax declined by 41% from INR 68.1 crore in FY23 to INR 40.4 crore in FY24.
-
Net Cash used in Operating activities was INR 344 crore in FY23 and INR 20 crore in FY24.
-
Cash flow from investing activities was INR 325 crore in FY23 and Net Cash used in investing activities was INR 21 crore in FY24.
-
Net cash used in Financing activities was INR 2 crore in FY23 and INR 1 crore in FY24.
Fundamentals
Financials
All values are INR Cr except per share value
| P&L Statement | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | 186.31 | 205.16 | 146.15 |
| Other Income | 25.79 | 24.08 | 34.29 |
| COGS | 49.96 | 47.14 | 41.24 |
| Gross Profit | 162.14 | 182.10 | 139.20 |
| Total Expense | 65.12 | 85.88 | 78.77 |
| EBIDTA | 97.02 | 96.23 | 60.44 |
| D&A | 3.45 | 3.93 | 4.63 |
| EBIT | 93.57 | 92.30 | 55.80 |
| Interest Expense | 0.16 | 0.22 | 0.58 |
| PBT | 93.42 | 92.08 | 55.22 |
| TAX | 23.26 | 24.02 | 14.79 |
| PAT | 70.16 | 68.06 | 40.43 |
| Diluted EPS | 175.57 | 170.34 | 101.17 |
| Basic EPS | 175.57 | 170.34 | 101.17 |
| Total income | 212.10 | 229.24 | 180.44 |
ASSETS
| CURRENT ASSETS | 2022 | 2023 | 2024 |
|---|---|---|---|
| Cash and Cash Equivalents | 21.33 | 0.82 | 0.25 |
| Trade Payables | - | 1.37 | 1.97 |
| Inventory | 24.11 | 18.81 | 30.46 |
| Other Current Assets | 428.14 | 512.46 | 541.95 |
| Total Current Assets | 473.58 | 533.46 | 574.63 |
| NON CURRENT ASSETS | 2022 | 2023 | 2024 |
|---|---|---|---|
| Plant Property and Equipment | 13.39 | 18.94 | 17.76 |
| Long Term Investment | 55.52 | 62.18 | 69.57 |
| Other Non Current Assets | - | 0.01 | - |
| Total Non Current Assets | 68.91 | 81.13 | 87.33 |
| Total Assets | 542.49 | 614.59 | 661.96 |
|---|
| CURRENT LIABILITES | 2022 | 2023 | 2024 |
|---|---|---|---|
| TRADW Payable | 7.28 | 9.73 | 16.83 |
| Other Current Liab | 6.74 | 10.58 | 12.34 |
| NON CURRENTLIABILITIES | 2022 | 2023 | 2024 |
|---|---|---|---|
| Deffered Tax Liab | 0.15 | - | 0.13 |
| Other Non Current Liab | 1.07 | 1.07 | 0.60 |
LIABILITIES
| EQUITY | 2022 | 2023 | 2024 |
|---|---|---|---|
| Share Capital | 4.00 | 4.00 | 4.00 |
| Other Equity | 523.33 | 589.29 | 628.07 |
| Total Equity | 527.33 | 593.29 | 632.07 |
| Total Liabilities & Equity | 527.33 | 593.29 | 632.07 |
|---|
| CASH FLOW STAT | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Cash Flow from operating | - | 152.19 | -344.02 | 19.57 |
| Cash Flow from financing | - | -0.68 | -1.94 | 1.07 |
| Cash Flow from investing | - | -132.49 | 325.44 | -21.22 |
| Net cash flow | 0.00 | 19.02 | -20.52 | -0.58 |
Revenue Growth
PAT Growth %
EPS Growth %
TOTAL ASSETS Growth %
QUICK RATIO Growth %
LONG TERM DEBT TO EQUITY RATIO Growth %
Shareholding Pattern
2026
| Name | Designation | Share % |
|---|---|---|
| Chang Investchem Private Limited | NA | 37.53% |
| Aessen Private Limited | NA | 20.51% |
| Acme Network S.A | NA | 20.07% |
| Others | NA | 21.88% |
Events
| Name | Date | Details |
|---|---|---|
| No events available. | ||
Frequently Asked Questions
- The lockin period is of 6 months for pre-ipo investors i.e. they cannot sell their shares for 6 months after they get listed. However, they can definitely sell the shares in pre-ipo market before they get listed.
- With BharatInvest, you can now invest in unlisted/pre-ipo shares with as low as 25-50k depending upon the share.
- 1. You can download the NSDL or CDSL application and login into the account and check whether the shares have been credited or not.
- 2. Credit of Unlisted Shares/Pre-IPO shares can be checked in brokers application as well but it takes T+2 days to show the shares.
- The value of share in unlisted space is determined in the same way as it is done in listed market. Demand and supply decide the price of any share. If the demand more than the supply, then the prices of the share increases and vice versa.
- When a new shares is introduces in the unlisted space, the value of the company is decided upon the last funding raised by company. If the company hasn’t raised any funding in the past, then the valuation is decided upon the fundamentals of the company.
- A Public Unlisted Shares Is Not Listed on Stock Exchange, Where as a Listed Public Company Is Listed On Stock Exchange Such As BSE Or NSE For Trading Of Shares.
- If you sell your shares within 2 years, then you will have to pay Short-term Capital gain on unli sted shares. Short-Term Capital Gain is added in your Income. So, as per individual tax slab you need to pay capital gain tax.
- If you sell your shares after 2 years, then you will have to pay Long-term Capital gain on unlisted shares LTCG is 12.5% without indexation benefits.
- After listing of shares, the unlisted shares which you have bought through unlisted market, will be taxed at listed rates, if sold through exchange. So, taxes of listed market will be applicable. And, to calculate holding time, for determining LTCG or STCG, the purchase date of unlisted shares will be applicable.
- Absoluetly NOT! Grey market is all about speculation relation to open price, subscription rate etc. And does not include physical delivery of shares. Whereas in pre ipo market you get to invest in shares much before the ipo too and it involves physical delivery of shares. It is compeletly legal and does not include any such speculation.
- Existing stakeholders, promoters or employees who have equity shares of an unlisted company and early investors who wish to get value of their investment.
- Yes, investing in unlisted shares is undoubtedly legal in India. The trading takes place in the over-the-counter market.